Hubbry Logo
IohexolIohexolMain
Open search
Iohexol
Community hub
Iohexol
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Iohexol
Iohexol
Iohexol
View on Wikipedia
from Wikipedia

Iohexol
Clinical data
Trade namesIodaque, Hexopaque, Oraltag, others
Other names5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		Intrathecal, intravascular, by mouth, intracavital, rectal
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein bindingLow
MetabolismNil
Elimination half-lifeVariable
ExcretionKidney, unchanged
Identifiers
  • 1-N,3-N-Bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.060.130 Edit this at Wikidata
Chemical and physical data
FormulaC19H26I3N3O9
Molar mass821.142 g·mol−1
3D model (JSmol)
Melting point174 to 180 °C (345 to 356 °F)
  • O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCC(O)CO)C(=O)NCC(O)CO)CC(O)CO)C
  • InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34) checkY
  • Key:NTHXOOBQLCIOLC-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Iohexol, sold under the trade names Omnipaque and Iodaque among others, is a contrast agent used for X-ray imaging.[3] This includes when visualizing arteries, veins, ventricles of the brain, the urinary system, and joints, as well as during computed tomography (CT scan).[3] It is given by mouth, injection into a vein, or into a body cavity.[4]

Side effects include vomiting, skin flushing, headache, itchiness, kidney problems, and low blood pressure.[3] Less commonly allergic reactions or seizures may occur.[3] Allergies to povidone-iodine or shellfish do not affect the risk of side effects more than other allergies.[5] Use in the later part of pregnancy may cause hypothyroidism in the baby.[6] Iohexol is an iodinated non-ionic radiocontrast agent.[3] It is in the low osmolar family.[7]

Iohexol was approved for medical use in 1985.[8] It is on the World Health Organization's List of Essential Medicines.[9][4]

Chemistry

[edit]

The osmolality of iohexol ranges from 322 mOsm/kg—approximately 1.1 times that of blood plasma—to 844 mOsm/kg, almost three times that of blood.[10] Despite this difference, iohexol is still considered a low-osmolality contrast agent; the osmolality of older agents, such as diatrizoate, may be more than twice as high.[11]

Adverse effects

[edit]

The most common side effects after intravenous injections are: pain at the site of injection (3%), blurring of vision (2%), nausea (2%), arrhythmia (2%), taste perversion (1%), hypotension (0.7%), and vomiting (0.7%).[12]

Society and culture

[edit]

Naming

[edit]

It is sold under the brand name Omnipaque.[13] It is also sold as a density gradient medium under the names Accudenz, Histodenz, and Nycodenz.[14][15]

Available forms

[edit]

It is available in various concentrations, from 140[12] to 350[16] milligrams of iodine per milliliter.[12] Iohexol can given as intrathecal, intravascular, oral, rectal, intraarticular, or into the body cavity.[12]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Iohexol

View on Grokipedia
from Grokipedia
Iohexol is a nonionic, water-soluble, agent used in radiographic to enhance the of internal body structures, such as vessels, organs, and the , during procedures like computed tomography (CT) scans, , , and arthrography. Marketed under the name Omnipaque and generic following FDA approval in November 2025, it is available in sterile solutions at iodine concentrations ranging from 140 to 350 mgI/mL, allowing for administration via intravascular, intrathecal, oral, rectal, or intra-articular routes depending on the diagnostic need. As a low-osmolar agent with an osmolality approximately 1.1 to 3.0 times that of plasma, iohexol minimizes the of osmotic-related adverse effects compared to high-osmolar ionic contrasts, making it suitable for use in adults, children, and patients with cardiovascular or renal conditions when appropriately dosed. Its primary indications include contrast enhancement for CT imaging of the head, , and ; excretory urography; intra-arterial and intravenous ; and evaluation of joint spaces or the . Contraindications include known to iohexol, with warnings emphasizing of allergic reactions, seizures (particularly with intrathecal use), and renal impairment in susceptible individuals; severe is a risk factor requiring hydration precautions. Chemically, iohexol is the compound 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide, with the molecular formula C19H26I3N3O9 and a molecular weight of 821.14 Da, containing 46.36% organically bound iodine by weight. Pharmacologically, it attenuates X-rays through iodine's high , providing radiopacity without dissociation into ions, and is rapidly cleared from the body via glomerular filtration in the kidneys, with a plasma half-life of about 2 hours following intravascular administration. This renal elimination underscores the need for hydration and monitoring in patients with impaired kidney function to prevent contrast-induced nephropathy.

Medical uses

Indications

Iohexol is a non-ionic medium primarily used to enhance visibility of internal structures in X-ray-based diagnostic imaging procedures. It works by providing radiopacity through its iodine content, allowing for clearer delineation of anatomical features during various radiological examinations. For intravascular administration, iohexol is indicated in of arteries and veins, including cerebral arteriography, peripheral arteriography, aortography, selective coronary arteriography, pulmonary in pediatric patients, and intra-arterial digital subtraction , as well as for intravenous contrast enhancement in computed (CT) scans of the head, body, and extremities, excretory urography, peripheral venography, and intravenous digital subtraction . Intrathecal use is approved for and CT (lumbar, thoracic, cervical, total columnar) and CT cisternography to visualize the brain ventricles and spinal subarachnoid spaces. Oral or rectal administration supports gastrointestinal tract opacification for radiographic examination and CT of the and . Intra-articular injection is indicated for arthrography to assess joint structures. In body cavity procedures, iohexol is used for (in non-pregnant adults), , herniography, and to evaluate the urinary tract and other cavities. These applications enable detailed visualization of blood vessels, the urinary tract, brain ventricles, and joints, facilitating accurate diagnosis in diverse clinical scenarios. Due to its essential role in these diagnostic imaging techniques, iohexol is included on the Organization's Model of under radiocontrast media.

Administration and dosage

Iohexol is administered via multiple routes depending on the procedure, including intravenous (IV) for computed (CT) and , intrathecal for , oral for gastrointestinal () tract visualization, rectal for lower studies, intra-articular for , and direct injection into body cavities such as during endoscopic retrograde pancreatography () or . The of route is guided by the specific diagnostic indication, with IV being the most common for systemic contrast enhancement in CT scans. Dosage is determined by the iodine concentration of the , ranging from 140 to 350 mgI/mL for injectable forms, and tailored to weight, age, and procedure type. For IV administration in adult CT head , typical doses are 70-150 mL of mgI/mL or 80 mL of 350 mgI/mL, administered as a bolus or ; for body CT, 50-200 mL of mgI/mL is used. In intrathecal , adults receive 6-17 mL of 180- mgI/mL (total iodine 1.2-3.06 gI), injected slowly over 1-2 minutes, while pediatric doses are lower at 2-15 mL of 180 mgI/mL (total up to 2.7 gI), adjusted by age and weight. For CT of the and , involves 500-1000 mL diluted to 6-12 mgI/mL, often combined with IV dosing; for radiographic examination of the GI tract, 50-100 mL of undiluted 350 mgI/mL may be used. Rectal doses for lower GI studies are similar in volume but delivered via enema. Intra-articular injections for arthrography use 5-20 mL of 240-350 mgI/mL, and body cavity injections vary from 10-100 mL based on the site. Maximum total iodine doses are limited, such as 250-290 mL (up to 87.5-101.5 gI) for IV/IA procedures and under 3.06 gI for intrathecal use to minimize risks. Preparation involves using sterile technique for all injections, inspecting solutions for particulates or discoloration, and administering at body temperature (37°C) or (20-25°C); oral solutions may be diluted with water, juice, or milk just prior to use. Single-use vials should be discarded after partial withdrawal to prevent contamination. Hydration protocols are essential, with patients encouraged to drink fluids before and after parenteral administration to reduce the risk of contrast-induced nephropathy. Special considerations include dose reductions for pediatric patients (e.g., 1-3 mL/kg IV for CT) and those with renal impairment, where the minimum effective dose is used; for allergy-prone individuals, premedication may be employed, though routine doses are not recommended—instead, emergency resuscitation equipment must be available. Dosing intervals, such as 48 hours between intrathecal exams, help prevent cumulative toxicity.
RouteExample Adult DosageConcentration (mgI/mL)Notes
Intravenous (CT)70-150 mL bolusAdjust for ; max 150 mL
Intrathecal ()6-17 mL180-Slow injection; max 3.06
Oral ( CT)500-1000 mL diluted6-1220-60 min pre-IV; pediatric max 5 (<3 years) to 10 (3-18 years)
Intra-articular5-20 mL240-350For only

Pharmacology

Iohexol is a non-ionic, water-soluble agent that provides radiopacity primarily through the high of its iodine atoms (Z=53), which effectively attenuate s via photoelectric absorption and . In photoelectric absorption, an incident is completely absorbed by an inner-shell electron of the iodine atom, ejecting the electron and leading to subsequent characteristic radiation or Auger electron emission; this process is particularly efficient at diagnostic energies near iodine's K-absorption edge of 33.2 keV. , meanwhile, involves partial energy transfer from the to an outer-shell electron, scattering the at an angle and contributing to overall attenuation, though it is less dependent on . The degree of radiopacity is directly proportional to the concentration of iodine in the solution, typically ranging from 140 to 350 mgI/mL in iohexol formulations, allowing for enhanced visualization of vascular structures and organs in procedures such as computed (CT) and angiography. As a non-ionic , iohexol exhibits low osmolality, approximately 322–844 mOsm/kg depending on the iodine concentration, which is closer to that of plasma (around 290 mOsm/kg) compared to high-osmolality ionic contrast agents. This reduced hypertonicity minimizes osmotic disruptions to vascular and tissues, such as , , or heat sensations during administration, thereby improving patient tolerability without compromising efficacy. Following intravascular or , iohexol rapidly diffuses into spaces, including blood vessels, interstitial tissues, and cerebrospinal fluid, where it enhances contrast by opacifying these compartments without significant penetration into cells or across intact biological barriers like the blood-brain barrier. It exhibits no intrinsic pharmacological activity beyond its radiopaque properties and remains in biological systems, with effects limited to those arising from its osmolality; there is no evidence of , deiodination, or binding to serum proteins that could alter its contrast-enhancing function.

Pharmacokinetics

Iohexol exhibits route-dependent absorption characteristics suited to its diagnostic applications. Intravenous administration results in immediate and complete entry into the bloodstream, achieving rapid peak plasma concentrations. Intrathecal injection leads to absorption from the into systemic circulation, with plasma levels peaking 2–6 hours post-administration. yields minimal systemic absorption, with only 0.1–0.5% of the dose excreted renally, enabling localized gastrointestinal effects without substantial body-wide exposure. Once absorbed, iohexol distributes predominantly within the extracellular fluid compartment, reflected in a of approximately 0.2–0.3 L/kg following intravenous dosing. It demonstrates negligible protein binding (<1%) and limited penetration of the intact blood-brain barrier. After intrathecal use, iohexol crosses the blood-brain barrier slowly, contributing to its utility in myelography. Iohexol is not metabolized in the body and is eliminated entirely in its unchanged form. Excretion of iohexol occurs almost exclusively through renal glomerular filtration, with 90–100% of an administered dose recovered in urine within 24 hours in individuals with normal renal function. The elimination half-life averages 1–2 hours under these conditions, accompanied by a urinary clearance of 100–120 mL/min. In renal impairment, clearance diminishes markedly, extending the half-life to over 20 hours and elevating the risk of prolonged exposure. Pharmacokinetic parameters of iohexol can vary with physiological and pathological states. Reduced clearance is observed in dehydration, renal disease, and elderly patients, where glomerular filtration rates are compromised. In abnormal tissues, such as tumors, iohexol distribution and enhancement timing may differ from normal tissues, often peaking immediately after administration but persisting variably.

Safety profile

Adverse effects

Iohexol administration, particularly via the intravascular route, is associated with a range of adverse effects, most of which are mild and transient. Common effects occurring in more than 1% of patients include warmth or pain at the injection site (approximately 3%), nausea (2%), headache (2%), vomiting (0.7%), altered taste (1%), and hypotension (0.7%). Flushing and a metallic taste are also frequently reported as physiologic responses. Recent meta-analyses indicate an overall acute adverse reaction rate of approximately 0.7% (95% CI, 0.5–1.0%) for intravascular use of non-ionic low-osmolar agents like iohexol, which is lower than historical rates for ionic contrast media. Serious adverse effects are rare, occurring in less than 1% of cases. These include contrast-induced nephropathy, with elevated risk in dehydrated patients or those with pre-existing renal impairment. Allergic-like reactions such as urticaria (0.3%), bronchospasm, and anaphylaxis (<0.04%) have been documented, alongside seizures (particularly with intrathecal administration, 0.01–0.3%). The iodine load from iohexol can lead to thyroid dysfunction, including hyperthyroidism or hypothyroidism, especially in susceptible individuals. Adverse effects vary by administration route. Intrathecal use carries risks of meningeal irritation and arachnoiditis, with headache reported in up to 18% of cases, alongside backache, neck stiffness (8%), nausea (6%), and vomiting (3%). Oral administration results in minimal systemic effects, primarily gastrointestinal symptoms like diarrhea (up to 42% in pass-through studies), nausea (15%), and vomiting (11%), which are generally self-limiting. Management of adverse effects involves monitoring for delayed reactions, which may occur up to 7 days post-administration, and supportive care such as hydration maintenance to mitigate risks like nephropathy. In clinical settings, emergency facilities should be available for 30–60 minutes following intravascular injection to address potential severe reactions.

Contraindications and precautions

Iohexol is contraindicated in patients with known hypersensitivity to iohexol or other iodinated contrast media due to the risk of severe allergic reactions. Use iohexol with caution in patients with manifest hyperthyroidism or recent iodine exposure, as these conditions may increase the risk of thyrotoxicosis or thyroid storm; evaluate and monitor thyroid function as appropriate. For hysterosalpingography, iohexol is absolutely contraindicated during pregnancy or suspected pregnancy, during menstruation or when menstruation is imminent, within 6 months after termination of pregnancy, within 30 days after conization or curettage, in the presence of genital tract infection, or with known or suspected reproductive tract neoplasia due to potential fetal harm or risk of peritoneal spread. Relative contraindications and precautions include severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², where the risk of contrast-induced nephropathy is heightened; in such cases, the lowest possible dose should be used. Additional risk factors necessitating caution are dehydration, diabetes mellitus, congestive heart failure, asthma, history of prior contrast reactions, advanced age, neonatal or debilitated status, and concurrent use of nephrotoxic drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), all of which elevate the potential for nephrotoxicity or allergic responses. Iohexol should be avoided or used with extreme caution in patients with pheochromocytoma or sickle cell disease, as limited data suggest possible exacerbation of hemodynamic instability or sickling crises, respectively. Pre-procedure precautions involve assessing renal function via serum creatinine to calculate eGFR, ensuring adequate hydration (e.g., intravenous normal saline before and after administration), and reviewing asthma medications or history of allergies to consider premedication with corticosteroids and antihistamines. Post-procedure monitoring for hypersensitivity, cardiovascular effects, or renal function changes is recommended for 24 to 48 hours, particularly in at-risk patients, with emergency equipment readily available. In special populations, iohexol is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data; it should be used only if clearly needed, as it crosses the placenta in small amounts. For breastfeeding individuals, it is advisable to pump and discard milk for 10 hours after administration to minimize infant exposure, though the amount excreted in breast milk is minimal. In pediatrics, dosing must be weight-based (typically 1.5 to 2 mL/kg), with heightened caution due to greater sensitivity to osmolality differences; low-osmolality formulations like iohexol are preferred, and thyroid function should be monitored in neonates and infants under 4 months, especially those with risk factors.

Chemistry

Molecular structure

Iohexol has the molecular formula C19H26I3N3O9 and a molecular weight of 821.14 g/mol. Its IUPAC name is 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide. The molecular structure of iohexol features a central ring substituted with three iodine atoms at the 2, 4, and 6 positions, providing radiopacity for its use as a . Attached to the 1 and 3 positions of the ring are carboxamide groups, each linked to a 2,3-dihydroxypropyl chain, while the 5 position bears an acetylated amino group also connected to a 2,3-dihydroxypropyl moiety. This arrangement can be visualized as a tri-iodinated core with two symmetric carboxamide arms extending to dihydroxypropyl groups and a third, acetyl-capped arm at the opposite side. Key structural characteristics include the non-ionic nature of the molecule, arising from the absence of charged groups, which differentiates it from earlier ionic s and contributes to lower osmolality in solution. The multiple hydroxyl groups on the side chains enhance solubility without introducing ionicity.

Physicochemical properties

Iohexol is a highly -soluble nonionic , with exceeding 500 mg/mL in attributable to its multiple hydrophilic hydroxyl groups. Aqueous solutions remain stable at 6.8–7.7, adjusted with or . The osmolality of iohexol formulations varies with iodine concentration, ranging from 322 mOsm/kg water for 140 mgI/mL solutions to 844 mOsm/kg water for 350 mgI/mL solutions, yielding an osmolality ratio to plasma (approximately 285 mOsm/kg) of 1.1 to 3.0. Viscosity increases with concentration and decreases with temperature; for example, values at 37°C range from 1.5 mPa·s for lower concentrations to 10.4 mPa·s for 350 mgI/mL, while at 20°C they span 2.3 to 20.4 mPa·s. Iohexol exhibits high stability, with no significant degradation during heat sterilization by autoclaving and no need for preservatives in formulations containing tromethamine and edetate calcium disodium as stabilizers. The iodine content is 46.36% by weight. Clinical formulations present as clear, colorless to pale yellow solutions.

History

Development

Iohexol was invented in the 1970s by the Norwegian pharmaceutical company Nycomed (originally Nyegaard & Co., now part of ) as part of a broader initiative to create safer non-ionic, low-osmolality contrast media for radiographic . The concept for non-ionic agents originated from Swedish radiologist Torsten Almén, who in 1968 proposed designing contrast media that do not dissociate into ions in solution to minimize osmolality-related side effects; Nyegaard & Co. adopted this idea and began collaborative development that year. This effort built on the company's earlier success with metrizamide, the first non-ionic agent introduced in 1974, but focused on improving stability and ease of use for broader clinical applications. The development of iohexol responded directly to the shortcomings of earlier high-osmolar ionic contrast agents, such as , which often induced patient discomfort including and sensations upon injection, as well as physiological issues like and hemodynamic instability due to their hyperosmolar nature (typically 5–8 times that of plasma). To address these, iohexol was engineered as a water-soluble, non-ionic featuring a tri-iodinated core with hydrophilic side chains, including neutral groups, that prevented while achieving an osmolality closer to plasma levels (approximately 2–3 times depending on concentration). This design prioritized reduced chemotoxicity and osmotoxicity without compromising radiopacity or solubility. Key milestones in iohexol's development included extensive preclinical testing throughout the , which demonstrated its lower toxicity profile in animal models compared to ionic agents; for instance, studies in dogs and showed minimal effects on cardiovascular parameters, blood-brain barrier integrity, and renal function at doses equivalent to clinical use. These findings paved the way for rigorous animal and early pharmacologic trials, which confirmed iohexol's superior safety margins, including fewer disruptions to electrophysiologic and hemodynamic functions. As a second-generation non-ionic agent, iohexol was developed in parallel with contemporaries like iopamidol (by Bracco in ) and ioversol (by in the ), all emphasizing enhanced hydrophilicity and non-ionic properties to further diminish adverse reactions associated with first-generation ionic media.

Regulatory approvals

Iohexol received initial regulatory approval in during the early , following its development by Nyegaard & Co. in , where it was introduced as a non-ionic for clinical use. In the United States, the (FDA) granted approval for iohexol, marketed as Omnipaque, in 1985 under (NDA) 018956 for intravascular and in diagnostic procedures. Subsequent expansions included FDA supplements to broaden indications; for instance, a 1993 supplemental approval (NDA 018956-S28) extended use for additional concentrations and pediatric applications in angiography and other procedures. In 2015, the FDA approved an oral formulation of iohexol as Oraltag (NDA 205383) for opacification of the gastrointestinal tract in computed tomography (CT) scans, marking the first low-osmolar iodinated contrast agent for oral use in this context. In November 2025, the FDA approved the first generic version of iohexol injection (Amneal Pharmaceuticals), expected to launch in early 2026. Globally, iohexol was added to the (WHO) Model List of Essential Medicines in the 21st edition published in 2019, recognizing its role in diagnostic imaging, particularly for excretory urography and CT enhancement; this inclusion was reaffirmed in the 23rd list in 2023 and the 24th list in 2025. Post-approval monitoring has included updates from regulatory bodies, such as Health 's 2024 approval of Omnipaque injection for oral use—the first such low-osmolar agent in —alongside ongoing safety reviews addressing rare adverse reactions like in young children. No major withdrawals have occurred, reflecting iohexol's established safety profile for approved indications.

Society and culture

Brand names and availability

Iohexol is primarily marketed under the brand name Omnipaque by , which has been available worldwide since its initial approval in 1985. Another brand is Oraltag, a for oral solution formulation developed by Interpharma Praha, an Otsuka subsidiary, and launched in the United States in 2016. GE Healthcare remains the main manufacturer, though generic versions of iohexol have been approved in various international markets following patent expiration. In November 2025, the U.S. FDA approved the first generic version of iohexol injection (300 mgI/mL) by . Iohexol is available by prescription only in most countries, including the and , and is widely accessible in hospital settings for radiological procedures. Its inclusion on the World Health Organization's Model List of facilitates distribution in over 100 countries. Outside , iohexol is used as a non-ionic density gradient medium under the brand Nycodenz for applications such as cell and isolation in settings.

Available forms

Iohexol is formulated as a sterile, pyrogen-free, colorless to pale-yellow for injection, available in iodine concentrations of 140, 180, , , and 350 mgI/mL. These solutions are supplied in vials and bottles ranging from 10 mL to 200 mL, with larger 500 mL bulk packages available for select concentrations ( and 350 mgI/mL), suitable for intravenous, intrathecal, and intra-articular administration. Pre-filled syringes containing iohexol, such as those at mgI/mL in 50 mL volumes, are also available for procedures. For gastrointestinal imaging, iohexol under Omnipaque is provided as an oral solution in concentrations of 9 mgI/mL or 12 mgI/mL, packaged in polymer bottles with volumes ranging from 180 mL to 1000 mL. Oraltag is supplied as a powder containing 9.7 g iohexol (equivalent to 4.5 g organically bound iodine) in a graduated single-use bottle for reconstitution with water to achieve similar concentrations (e.g., 9 mgI/mL) in volumes up to 500 mL. No solid or topical preparations of iohexol exist. All iohexol formulations are preservative-free and contain tromethamine (1.21 mg/mL) and edetate calcium disodium (0.1 mg/mL) as stabilizers, with pH adjusted to 6.8–7.7 using or . Osmolality varies by concentration, ranging from approximately 322 mOsm/kg (140 mgI/mL) to 844 mOsm/kg (350 mgI/mL). Storage requires room temperature (20–25°C; excursions permitted to 15–30°C), protection from light, and avoidance of freezing to maintain stability.

Naming

Iohexol is the (INN) recommended by the (WHO) for this non-ionic agent, facilitating its global identification independent of commercial branding. The systematic IUPAC name for iohexol is 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide, which reflects its core consisting of a triiodinated isophthalamide backbone with hydrophilic side chains. No standardized abbreviations exist specifically for iohexol, although it is generically categorized and referred to as a low-osmolar contrast medium (LOCM) in due to its osmolality profile relative to plasma. Iohexol was developed by the Norwegian pharmaceutical company Nycomed in the late under internal code names prior to its formal assignment and subsequent commercialization in the early .

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018956s116,020608s049lbl.pdf
  2. https://go.drugbank.com/drugs/DB01362
  3. https://www.mayoclinic.org/drugs-supplements/iohexol-oral-route/description/drg-20406805
  4. https://pubchem.ncbi.nlm.nih.gov/compound/Iohexol
  5. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020608s047lbl.pdf
  6. https://list.essentialmeds.org/medicines/168
  7. https://www.gehealthcare.com/-/jssmedia/GEHC/US/Files/Products/Contrast-Media/Omnipaque/omnipaque-uspi.pdf
  8. https://reference.medscape.com/drug/omnipaque-oraltag-iohexol-343760
  9. https://www.drugs.com/dosage/iohexol.html
  10. https://radiopaedia.org/articles/iodinated-contrast-media-1?lang=us
  11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018956s099lbl.pdf
  12. https://pdf.hres.ca/dpd_pm/00040927.PDF
  13. https://pubmed.ncbi.nlm.nih.gov/6408018/
  14. https://www.nature.com/articles/s41598-021-01892-1
  15. https://www.gehealthcare.com/-/jssmedia/c66966a70fe946afa829483a1d6c848c.pdf
  16. https://link.springer.com/article/10.1007/s00330-025-11526-z
  17. https://www.cmaj.ca/content/172/11/1461
  18. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1108674
  19. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9e9d558-064c-4b86-8d96-2f8a678c89f9
  20. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018956s101lbl.pdf
  21. https://uwaterloo.ca/chem13-news-magazine/march-2016/chemistry/iohexol-ct-scan-contrast-agent-compound-containing-iodine
  22. https://jcpres.com/storage/upload/pdfs/EMJ_43_6_626_630.pdf
  23. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018956-s28_omnipaque_toc.cfm
  24. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/205383Orig1s000ltr.pdf
  25. https://www.biospace.com/press-releases/amneal-receives-u-s-fda-approval-for-iohexol-injection
  26. https://www.iccp-portal.org/sites/default/files/resources/WHO-MVP-EMP-IAU-2019.06-eng.pdf
  27. https://www.dra.gov.pk/wp-content/uploads/2023/10/WHO-Essential-Medicines-List-02.10.2023.pdf
  28. https://www.who.int/publications/i/item/B09474
  29. https://car.ca/news/the-first-and-only-low-osmolar-iodinated-contrast-media-approved-for-oral-use-in-canada/
  30. https://www.gehealthcare.com/products/contrast-media/omnipaque
  31. https://www.otsuka.co.jp/en/company/newsreleases/2016/20160705_1.html
  32. https://www.beilupharma.com/iohexol-injection-passed-the-consistency-evaluation-for-generic-drugs.html
  33. https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U-S--FDA-Approval-for-Iohexol-Injection/default.aspx
  34. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1710787451238
  35. https://www.gehealthcare.in/products/contrast-media/omnipaque-at
  36. https://us.progen.com/Nycodenz-Iohexol/18003
  37. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eee15ebe-d349-4497-acef-6abe7a8247fb
  38. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdeb1668-7126-48f7-aaf9-1dc3beb90bac
  39. https://www.who.int/teams/health-product-and-policy-standards/inn
  40. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2262877.htm
  41. https://patents.google.com/patent/US4250113A/en
Add your contribution
Related Hubs
User Avatar
No comments yet.